Critical Quality Attributes in Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) combine three components — a monoclonal antibody, a linker, and a cytotoxic payload — into a single molecule, and each component introduces its own quality risks. Six critical quality attributes (CQAs) are consistently flagged by regulators for ADC programs: drug-to-antibody ratio (DAR), antibody size variants, payload distribution, unconjugated antibody, unconjugated drug (D0), and charge variants. All six require experimental characterization and risk assessment under ICH Q8(R2), and each has a direct, well-documented impact on either safety or efficacy.

For CMC teams, the practical challenge is not simply identifying ADC CQAs, but understanding which attributes are most likely to affect patient safety, product efficacy, and manufacturing consistency. This article outlines the six ADC CQAs most commonly prioritized during development and explains how they should be evaluated through analytical characterization and molecule-specific risk assessment.

Why ADCs Carry More CQA Risk Than a Standard Biologic

Because these three components are chemically conjugated rather than expressed as one uniform biomolecule, an ADC inherits heterogeneity from the antibody, linker, and payload at the same time. A batch of the same ADC can contain molecules with different drug loads, conjugation sites, charge profiles, and aggregation states, and those differences can change how the product distributes, binds, clears, and releases payload in the body.

The Three Building Blocks of an ADC

• Antibody — typically a monoclonal antibody engineered to target one or more specific antigens, though bispecific formats are also used. Its job is antigen recognition.
• Linker — the chemical bridge conjugated to the antibody at cysteine or lysine residues. Most linkers are designed to be cleavable inside the target cell, though non-cleavable linkers are also used depending on the mechanism of drug release.
• Drug (payload) — a synthetic small-molecule cytotoxin, sometimes described as the "warhead," responsible for destroying the cancer cell once released.

Because heterogeneity can originate from any of these three components, a comprehensive CQA assessment has to evaluate potency, stability, and toxicity risk across all three — not just the antibody backbone.

Why Regulators Focus on ADC CQAs

ICH Q8(R2) defines Critical Quality Attributes as physical, chemical, biological, or microbiological characteristics that must remain within appropriate limits to ensure product quality.

For ADCs, regulators expect sponsors to demonstrate:

• Product-specific CQA identification
• Scientific justification through risk assessment
• Robust analytical characterization
• Manufacturing consistency
• Appropriate process controls throughout development

Rather than prescribing a universal checklist, regulatory agencies expect developers to understand how each quality attribute affects safety, efficacy, and product performance for their specific molecule.

The Six CQAs That Matter Most for ADCs

Drug-to-Antibody Ratio (DAR)

DAR describes how many drug molecules, on average, are attached to each antibody. It is often treated as the most important ADC-specific CQA because it sits at the center of the therapeutic window: when DAR is too high, toxicity risk increases; when DAR is too low, the ADC may not deliver enough cytotoxic payload to be effective.

Antibody Size Variants

Aggregates, particles, and fragments change how the ADC behaves in circulation and at the target site, with direct consequences for both efficacy and safety. Size variant control is one of the more familiar CQAs from monoclonal antibody development, but conjugation adds new opportunities for aggregation to occur.

Payload Distribution

Even when the average DAR looks acceptable, the distribution of drug molecules across the antibody population matters. A random or overly broad distribution — some antibodies overloaded, others under-loaded — produces a mixed population with unpredictable efficacy and safety characteristics, even if the batch average appears normal.

Unconjugated Antibody

"Naked" antibody — antibody that never got conjugated to a linker-drug unit — is not simply inactive filler. It actively competes with the functional ADC for antigen binding sites, which can reduce overall efficacy. It is also more susceptible to aggregation under thermal stress, which raises immunogenicity concerns.

Unconjugated Drug (D0)

Free, unconjugated payload is a safety-critical impurity. Because it is no longer tethered to the targeting antibody, it can cause off-target cytotoxicity outside the intended tumor region. Unlike naked antibody, free payload does not compete for antigen binding; instead, it bypasses antibody-mediated targeting entirely, which is why controlling free drug levels is essential for ADC safety.

Charge Variants

Acidic and basic charge variants reflect differences in the molecule’s surface charge distribution and can influence stability, binding behavior, pharmacokinetics, and biological activity. For that reason, charge variant profiling is a standard part of ADC characterization panels.

Common Challenges in ADC Analytical Development

Even well-designed ADC programs encounter analytical challenges throughout development. Frequently observed issues include:

• DAR drift during process optimization
• Batch-to-batch variability
• Linker instability
• Payload degradation
• Co-eluting chromatographic species
• Method transfer between development and GMP laboratories
• Characterizing increasingly complex site-specific conjugates

Addressing these challenges early reduces downstream CMC risk by helping teams define appropriate control strategies, avoid late-stage method gaps, and generate more consistent data packages for regulatory review.

Turning CQA Data Into a Risk Assessment

Identifying these six attributes is only the starting point. Under ICH Q8(R2), each quality attribute should be evaluated through a risk assessment that considers its potential impact on patient safety, product efficacy, and overall product performance, as well as the level of uncertainty around that impact. Because criticality can vary by antibody format, linker chemistry, payload, conjugation strategy, and intended clinical use, experimental validation is needed to confirm which attributes are truly critical for a specific ADC molecule. This list should therefore be treated as a practical starting framework, not a universal checklist.

Analytical Approaches for ADC Characterization

Measuring these CQAs requires an analytical toolkit that spans protein characterization, small-molecule analysis, and functional bioassays.

• High-resolution LC-MS for DAR determination and payload distribution mapping
• Liquid-based chromatography — HIC, IEX, SEC, RPLC, CE, and cIEF — for size variants, charge variants, and conjugation profiling
• Binding and cell-based assays, including surrogate cytotoxicity assays and direct ADCC, ADCP, and CDC assays, for functional characterization
• Anti-ADC-antibody assays, qPCR, ELISA, endotoxin, sterility, bioburden, and cell-based bioassays for broader biologics quality attributes

This combination of high-resolution analytical chemistry and biologics-focused bioanalytical testing reflects the hybrid nature of ADCs themselves — part small molecule, part biologic, and fully dependent on both disciplines working together.

How Crystal Bio Solutions Supports ADC Development

At Crystal Bio Solutions, we provide integrated analytical and bioanalytical services that help ADC developers characterize key CQAs, build molecule-specific control strategies, and generate data packages to support IND-enabling studies and later-stage CMC activities.

Our capabilities include:

• High-resolution LC-MS characterization
• Orthogonal chromatography platforms (HIC, IEX, SEC, RPLC, CE, cIEF)
• DAR analysis
• Aggregation and charge variant analysis
• Method development and validation
• Cell-based bioassays
• Cytotoxicity assays
• ADCC, ADCP, and CDC functional assays
• ADA testing
• ELISA and qPCR
• Sterility, endotoxin, and bioburden testing

By combining advanced analytical technologies with regulatory experience, we help ADC developers translate complex CQA data into practical control strategies that support safer, more consistent, and more efficient development from discovery through clinical stages.

Frequently Asked Question

What is the most important CQA for an antibody-drug conjugate?

Drug-to-antibody ratio (DAR) is generally considered central, since it directly governs the balance between efficacy and toxicity. However, regulators expect all six attributes — DAR, size variants, payload distribution, unconjugated antibody, unconjugated drug, and charge variants — to be assessed for criticality. 

Why is unconjugated drug (D0) a safety concern?

D0 is free cytotoxic payload no longer attached to the targeting antibody. Without the antibody to direct it to the tumor, D0 can cause off-target cytotoxicity in healthy tissue.

Does a normal average DAR guarantee a safe, effective ADC?

Not necessarily. Payload distribution matters independently of average DAR — a batch can have an acceptable average while still containing a wide, uneven spread of drug-loading across individual antibody molecules, which can affect both efficacy and safety.

What analytical techniques are used to characterize ADC CQAs?

A combination of high-resolution LC-MS, liquid chromatography techniques (HIC, IEX, SEC, RPLC, CE, cIEF), and bioanalytical assays such as ADCC/ADCP/CDC and anti-ADC-antibody assays are typically used to cover the full range of ADC-related CQAs.

Which regulatory guideline governs CQA risk assessment for ADCs?

ICH Q8(R2) provides the framework for risk-assessing each quality attribute based on its potential patient impact, using a scoring approach that accounts for both impact and uncertainty.